Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3667 in Adult Subjects With Dermatomyositis
NCT05695950Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of GLPG3667 in dermatomyositis (DM), sponsored by Galapagos NV. Started Feb 2023; status: completed.
02
Drugs
GLPG3667
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05695950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695950.